EHC Encompass Health Corporation
Encompass Health Corporation operates inpatient rehabilitation hospitals in the United States and Puerto Rico. The company offers specialized rehabilitative treatment, using technology and therapy, on an inpatient basis for patients recovering from a major injury or illness and seeking to regain functional ability, independence, and quality of life; medical, nursing, therapy, and ancillary services; and rehabilitative care to patients who are recovering from conditions, such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations. It offers services through the Medicare program to the federal government, managed care plans and private insurers, state governments, and other patients. The company was formerly known as HealthSouth Corporation and changed its name to Encompass Health Corporation in January 2018. Encompass Health Corporation was incorporated in 1984 and is based in Birmingham, Alabama.…
Industry Peers
Medical Care FacilitiesKey Statistics
About Encompass Health (NYSE: EHC)
›
Encompass Health (NYSE: EHC) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Medical Care Facilities industry, part of the Healthcare sector, and reports about 29,875 employees.
The shares were at 133.65 USD on 20 November 2026, up 19.8% over 52 weeks. Its 52-week range is 92.77 USD to 143.90 USD: the price is 7.1% below the high and 44.1% above the low.
At a market capitalisation of 13.11B USD, it trades at 21.4 times trailing earnings and 19.4 times forward earnings. The median trailing P/E of its 18 largest Medical Care Facilities peers is 23.8, a discount of 10% for EHC. It pays a dividend yielding 0.64% (it pays out 12% of its earnings), against a median of 0.84% among the dividend payers in that peer group.
Encompass Health reports return on equity of 23.2%, an operating margin of 18.4% and revenue up 8.9% year over year.
Its debt exceeds its cash by 2.73B USD, a debt-to-equity ratio of 1.11. Its Piotroski F-score is 9 out of 9, a strong reading of its financial health. 12 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 156.08 USD is 16.8% above the current price. The next earnings report is expected on 4 February 2027.